TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36038256
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day caffeine citrate
Study: 36038256
Drug: 15 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/day caffeine citrate
Study: 36038256
Drug: 20 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg/day caffeine citrate
Study: 34018006
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid injection of triamcinolone acetonide (Kenalog)
Study: 33001143
Drug: Dostarlimab 500
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 500 mg intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, treatment discontinuation, or withdrawal
Study: 37053535
Drug: Trametinib (MEK1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (MEK1/2 inhibitor)
Study: 35699261
Drug: NRD.E1 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRD.E1 (300 to 1200 mg single dose)
Study: 35699261
Drug: NRD.E1 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRD.E1 (300 mg once daily for 5 days)
Study: 35699261
Drug: NRD.E1 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRD.E1 (40 mg under fed and fasted conditions)
Study: 33627370
Drug: Insomnia prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insomnia prevention program (4 weekly sessions)
Study: 35672057
Drug: Chemotherapy following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy following a dose adjusted EPOCH‐R regimen
Study: 33279779
Drug: Mesalamine induction
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine induction therapy
Study: 32660869
Drug: Trofinetide 70
Normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide 70 mg/kg twice daily
Study: 32660869
Drug: Trofinetide 35
Normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide 35 mg/kg twice daily
Study: 34707360
Drug: Hypotensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive treatment
Study: 34923163
Drug: Camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab plus chemotherapy (carboplatin and paclitaxel)
Study: 39102832
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (carboplatin and paclitaxel)
Study: 35568194
Drug: BNP <200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP <200 pg/mL (low)
Study: 35568194
Drug: BNP 200
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP 200 to <400 pg/mL (moderate)
Study: 35568194
Drug: BNP ≥400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP ≥400 pg/mL (high)
Study: 34684135
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy training (control group), n = 12
Study: 33979232
Drug: Single-use negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-use negative pressure wound therapy (sNPWT)
Study: 34735740
Drug: Psychodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic treatment for BPD
Study: 32331879
Drug: Flunixin meglumine
Normalized name: Flunixin Meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunixin meglumine (2.2 mg/kg of BW)
Study: 32331879
Drug: Isotonic sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sterile saline solution
Study: 37071836
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab
Study: 32234705
Drug: Intravenous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous rituximab
Study: 36114096
Drug: Nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (100 mg/m² on days 1, 8, and 15 of a 21-day cycle)
Study: 36114096
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m² on day 1)
Study: 32186967
Drug: Self-hypnosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-hypnosis treatment program
Study: 34331080
Drug: Topiramate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (up to 200 mg/day)
Study: 34740708
Drug: Blonanserin transdermal
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin transdermal patches (40-80 mg/day)
Study: 34740708
Drug: Blonanserin transdermal
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin transdermal patches
Study: 33007780
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 55 µg
Study: 33007780
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 µg
Study: 33752752
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen of post-operative antibiotics
Study: 33752752
Drug: 1-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-day regimen of post-operative antibiotics
Study: 36197309
Drug: AVT02 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT02 administered via prefilled syringe (PFS)
Study: 36197309
Drug: AVT02 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT02 administered via autoinjector (AI)
Study: 36197309
Drug: AVT02 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT02 administered via PFS
Study: 36197309
Drug: AVT02 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT02 administered via AI
Study: 36062569
Drug: Probiotics (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (4 g daily)
Study: 36062569
Drug: Metformin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.5 g daily)
Study: 36062569
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of probiotics and metformin
Study: 33705475
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) plus treatment as usual (TAU)
Study: 34410203
Drug: Group CBT
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group CBT treatment
Study: 34073401
Drug: Ivermectin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (single dose according to body weight)
Study: 34073401
Drug: Standard preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preventive treatment (mainly supplements)
Study: 33754455
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dosing (0.3 mg/kg/dose)
Study: 33754455
Drug: Divided dosing
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dosing (0.15 mg/kg/dose every 8 hours)
Study: 32195801
Drug: p‐COP‐determined iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: p‐COP‐determined iodine dose (Group A, n = 65)
Study: 35103587
Drug: FDC hard
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC hard capsule containing CC/HCTZ/RSV
Study: 32985902
Drug: Zanubrutinib plus
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib plus rituximab followed by zanubrutinib monotherapy
Study: 32783367
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist pretreatment (n=172)
Study: 32783367
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GnRH agonist pretreatment, n=171)
Study: 32345077
Drug: 0.25 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 µg alfacalcidol daily for 12 weeks
Study: 32154928
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg every 2 weeks plus trebananib 15 mg/kg every week
Study: 35038985
Drug: In-Home Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-Home Cognitive Processing Therapy (CPT)
Study: 35038985
Drug: Telehealth Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth Cognitive Processing Therapy (CPT)
Study: 35038985
Drug: In-Office Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-Office Cognitive Processing Therapy (CPT)
Study: 33327240
Drug: Oral Maxing
Normalized name: Bronkaid Max Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Maxing Shigan Decoction
Study: 33327240
Drug: Oral Qingfei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Qingfei Decoction
Study: 33766084
Drug: Melatonin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin supplementation (250 mg, two tablets once a day for 8 weeks)
Study: 33151634
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and behavioral therapy (CBT) plus antidepressants
Study: 33746024
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily)
Study: 33746024
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (aspirin 100 mg and clopidogrel 75 mg once daily combined with dose-adjusted warfarin)
Study: 33746024
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (ticagrelor plus rivaroxaban)
Study: 33746024
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (warfarin plus dual antiplatelet therapy)
Study: 32935904
Drug: Nopal fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nopal fiber 20 g/day
Study: 32935904
Drug: Nopal fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nopal fiber 30 g/day
Study: 32935904
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 g/day dextrose)
Study: 32682394
Drug: Early Oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Oral Hydration (EOH) - small amount of drinking water after recovery of swallowing reflex
Study: 32682394
Drug: Delayed Oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Oral Hydration (DOH) - water administered at 4 hours post-anesthesia
Study: 35617974
Drug: Lotion
Normalized name: LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: 32776570
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for ARFID (CBT-AR), 20–30 sessions delivered in family-based or individual format.
Study: 32776570
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for ARFID (CBT-AR)
Study: 36438970
Drug: Sham treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatments
Study: 35485618
Drug: ATVV stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATVV stimulation therapy
Study: 35388029
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions of psychotherapy for 12 months
Study: 32991776
Drug: CIN risk
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIN risk score model based on LVEF < 40%, acute coronary syndrome (ACS), eGFR < 60, and contrast volume > 300 mL.
Study: 34697566
Drug: Low-dose Betaloc
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Betaloc (≤47.5 mg)
Study: 34697566
Drug: Medium-dose Betaloc
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose Betaloc (47.5-95 mg)
Study: 34697566
Drug: High-dose Betaloc
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Betaloc (142.5-190 mg)
Study: 33963005
Drug: Automated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated oxygen titration with the VDL1.1 algorithm
Study: 35152918
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg vitamin B12 daily for a year
Study: 32674594
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for COVID-19 (specific interventions not detailed)
Study: 34793864
Drug: Preoperative accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative accelerated radiotherapy (AF) with 43 fractions, total dose of 68 Gy in 4.5 weeks followed by surgery
Study: 34793864
Drug: Postoperative conventionally
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative conventionally fractionated radiotherapy (CF), total dose of 60 or 66 Gy in 6-7 weeks
Study: 36585602
Drug: IL-17 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-17 inhibitors
Study: 35192788
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) in addition to standard medical care (SMC)
Study: 34444004
Drug: Immediate Treatment
Normalized name: Aquaphor Immediate Relief Lip Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Treatment Group (IT, n = 10)
Study: 36000293
Drug: Test linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test linezolid tablet (600 mg)
Study: 36000293
Drug: Reference linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference linezolid tablet (600 mg)
Study: 36000293
Drug: Test and
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test and Reference linezolid tablets
Study: 33735404
Drug: Diagnosis name
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis name (AMD) combined with fluorescence fundus angiography and/or anti‐VEGF treatment
Study: 33735404
Drug: Diagnosis name
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis name (AMD) combined with AMD treatment
Study: 35085443
Drug: Online administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online administration of the Test of Narrative Language-Second Edition (TNL-2)
Study: 35085443
Drug: In-person administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person administration of the Test of Narrative Language-Second Edition (TNL-2)
Study: 32422285
Drug: Topical castor
Normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical castor oil applied to one eye, twice daily for 4 weeks
Study: 32422285
Drug: Topical castor
Normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical castor oil applied to one eye
Study: 35863559
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg, three times per week via the hemodialysis circuit for 24 weeks
Study: 34521687
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg IV every 4 weeks for 24 weeks
Study: 34521687
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg IV
Study: 36477706
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg/kg
Study: 33845881
Drug: N-Acetylcysteine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetylcysteine (300 mg/kg equivalent to 20 gr as a slow single intravenous injection on the first day of hospitalization)
Study: 33845881
Drug: Placebo (Sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Sterile water for injection, identical in appearance to N-Acetylcysteine)
Study: 36075260
Drug: Rezvilutamide plus
Normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezvilutamide plus ADT (240 mg daily)
Study: 36075260
Drug: Bicalutamide plus
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide plus ADT (50 mg daily)
Study: 35689084
Drug: Low-Dose atDCS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose atDCS
Study: 35689084
Drug: High-Dose atDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose atDCS
Study: 35689084
Drug: Combined atDCS
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined atDCS group (Low-Dose + High-Dose)
Study: 36001383
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with standard platinum-based chemotherapy
Study: 39096924
Drug: Standard platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard platinum-based chemotherapy
Study: 32740081
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz translumbosacral neuromodulation therapy (TNT)
Study: 32740081
Drug: 5 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Hz translumbosacral neuromodulation therapy (TNT)
Study: 32740081
Drug: 15 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 Hz translumbosacral neuromodulation therapy (TNT)
Study: 32740081
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz and 5 Hz translumbosacral neuromodulation therapy (TNT)
Study: 32118463
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages containing accurate drinking norms (n = 61)
Study: 35972453
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal tablets, 100 mg twice daily, starting from the day of embryo transfer
Study: 33645069
Drug: Icaritin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icaritin (5 μmol·L(‐1))
Study: 33645069
Drug: Icaritin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icaritin (10 μmol·L(‐1))
Study: 33645069
Drug: Icaritin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icaritin (20 μmol·L(‐1))
Study: 34304346
Drug: Targeted antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotic prophylaxis based on rectal swab results
Study: 33727034
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (manual assessment three times daily using a portable manometer)
Study: 35503024
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioral Therapy (ICBT) for 7 weeks
Study: 32009486
Drug: 5-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-g oral collagen hydrolysate (CH) daily for 4 weeks
Study: 32623370
Drug: Drainage, irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drainage, irrigation and fibrinolytic therapy (DRIFT)
Study: 37149930
Drug: MSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC treatment
Study: 36398114
Drug: Low-Intensity Vibration
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Vibration (LIV) - 0.4 g at 30 Hz for 10 min/day
Study: 32840458
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping following Manual Therapy (KTMT)
Study: 34058071
Drug: GDC-0334 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0334 (25 mg starting dose)
Study: 33475753
Drug: No OSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No OSA management or treatment
Study: 36380290
Drug: Intervention for
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention for Appropriate Care and Treatment (InterACT) trial
Study: 35806937
Drug: Oral antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiplatelet treatment
Study: 32332636
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) with basic western medicine (BWC)
Study: 32332636
Drug: Basic western
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic western medicine (BWC)
Study: 32332636
Drug: Sham electroacupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroacupuncture (sham EA) with basic western medicine (BWC)
Study: 34392795
Drug: Constraint‐induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced movement therapy (CIMT) and neurostimulation paired with intensive, goal‐directed therapy
Study: 32005160
Drug: 20 mL ropivacaine
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL ropivacaine (7.5 mg/mL)
Study: 32005160
Drug: 20 mL saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL saline (placebo)
Study: 32959591
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with Yuyin pill
Study: 32959591
Drug: Yuyin pill
Normalized name: Yujin (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuyin pill alone